Since PBMCs contain the full complement of epigenetic enzymes found in most tissues, the investigators evaluated the role of DNA methylation in the regulation of ES gene transcription in all the enrolled subjects. DNA was extracted from whole blood using QIAmp DNA Blood Mini Kit and its concentration was determined by NanoDrop quantification. Arrays preparation and data analysis were performed by Genomix4Life srl. High-quality DNA (500 ng) was bisulfite converted using EZ DNA methylation kit. Bisulfite converted DNA (200ng) was used for analysis of whole-genome methylation, using the HumanMethylation 450 K BeadChip, which contains 485 577 probes covering 21 231 (99%) RefSeq genes.

Chronic Migraine

Ircss Mondino Foundation

Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients

Peripheral Gene Expression of Endocannabinoid System Components in Episodic and Chronic Migraine Patients: a Pilot Study

CB1 protein expression in the peripheral blood mononuclear cells (PBMCs)

CB2 protein expression in the peripheral blood mononuclear cells (PBMCs)

Gene expression of the endocannabinoid receptors in the peripheral blood mononuclear cells ( PBMCs)

Gene expression of the FAAH in the peripheral blood mononuclear cells ( PBMCs)

Gene expression of the NAPE-PLD in the peripheral blood mononuclear cells ( PBMCs)

Gene expression of the DAGL in the peripheral blood mononuclear cells ( PBMCs)

Gene expression of the MAGL in the peripheral blood mononuclear cells ( PBMCs)

DNA methylation in the regulation of ES gene transcription

IRCCS National Neurological Institute "C. Mondino" Foundation

Ministry of Health, Italy

Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days

Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water

Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily

Crown Lengthening Procedure With Ostectomy

CLP with ostectomy done in patients whose biologic width and crown height is insufficient

Arnica 200 drug 3 pills,3 times daily for 3 days

Diclofenac Sodium 50mg twice daily

Placebo pills and distilled water 3 pills,3 times daily

Dental

Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure

Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure: A Placebo Control Trial

Pain Assessment is done by visual analog scale which consists of 10 centimeter line. anchored by two extremes starting from 1 ending to 10, of which 1 being the lowest and 10 being highest score.

Dr.Nibha Suneel Kulkarni

Principal Investigator

Tatyasaheb Kore Dental College

Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

CYSTOID MACULAR EDEMA

Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Ranibizumab,

Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide

Soll Eye

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

To assess the safety of intravitreal R and T for the treatment of acute pseudophakic cystoid macular edema by evaluating:
Incidence and severity of ocular adverse events, as identified by eye examination
Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs

Mean change in spectral domain OCT CMT from baseline (microns)

Mean change in ETDRS letters from baseline (letters)

Proportion of patients with 3 line or better ETDRS letter improvement (%)

Time to 3 line ETDRS letter improvement (days)

Genentech, Inc.

500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3

300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3

500 mL of ringers lactate over 30 minutes to be administered prior to ECT for treatments 1,2 and 3
Placebo infusion: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3

Sugar Water

800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
ibuprofen intravenous: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3

Ibuprofen

Total

Sex: Female, Male

Region of Enrollment

examination of participants to confirm cognitive ability. Questions such as who is the president, what is the day of the week, the date. The scale is from 0-30. Value of 24 or higher indicates absence of cognitive impairment

Mini Mental State Examination >23

subject self reporting rating scale for severity of myalgias utilizing numeric rating scale 0= no pain, 1-3= mild pain, annoyance with little interference with Activities of Daily Living (ADL), 4-6= moderate (interferes significantly with ADL, 7-10 = severe pain unable to perform ADL

500 mL of ringers lactate over 30 minutes to be administered prior to ECT for treatment 1, at one hour following procedure

Sugar Water-one Hour After Treatment #1

800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
subject report of myalgia one hour after completion of procedure number 1

Ibuprofen One Hour After Treatment #1

Subject reported myalgia 6 hours after completion of treatment # 1,

Sugar Water 6 Hours After Procedure #1

subject reported myalgia 6 hours after treatment 1

Ibuprofen 6 Hours After Treatment #1

subject reported myalgia 24 hours after completion of procedure 1

Sugar Water 24 Hours After Treatment #1

subject reported myalgia 24 hours after procedure 1

Ibuprofen 24 Hours After Treatment 1

subject reported myalgia 48 hours after procedure 1

Sugar Water 48 Hours After Procedure 1

subject reported myalgia 48 hours after treatment day 1

Ibuprofen 48 Hours After Treatment 1

Subject Self Reported Numerical Rating of Incidence and Severity of Post-Electroconvulsive Therapy Myalgias After Treatment 1

Subject self reported numerical rating of incidence and severity of post ECT Myalgia after treatment day 2 0=no pain, 1-3=mild pain (annoying, little interference with ADL), 4-6= moderate,( interferes significantly with ADL) 7-10 severe pain (unable to perform everyday activities)

500 mL of ringers lactate over 30 minutes to be administered prior to ECT for treatments 2
Placebo infusion: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatment day 2

Sugar Water-one Hour After Treatment 2

800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 2 one hour after treatment
ibuprofen intravenous: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT treatment day 2

Ibuprofen One Hour After Treatment #2

Subject reported myalgia 6 hours after completion of treatment #2

Sugar Water 6 Hours After Procedure #2

Ibuprofen 6 Hours After Treatment #2

Subject reported myalgia 24 hours after completion of treatment #2

Sugar Water 24 Hours After Treatment #2

Ibuprofen 24 Hours After Treatment #2

Subject reported myalgia 48 hours after completion of treatment #2

Sugar Water 48 Hours After Treatment 2

Ibuprofen 48 Hours After Treatment 2

Myalgia Reported on Treatment Day 2

Subject self reported severity of myalgia based on a self reported assessment utilizing numeric rating scale 0=no myalgia, 1-3=mild myalgia (annoying, little interference with ADL);4-6=moderate (interferes significantly with ADL); 7-10 severe myalgia(unable to perform every day activities)

500 mL of ringers lactate over 30 minutes to be administered prior to ECT for treatments 3
Placebo infusion: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatment day 2

Sugar Water-one Hour After Treatment 3

800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 3 one hour after treatment
ibuprofen intravenous: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT treatment day 2

Ibuprofen One Hour After Treatment #3

Subject reported myalgia 6 hours after completion of treatment #3

Sugar Water 6 Hours After Procedure #3

Ibuprofen 6 Hours After Treatment #3

Subject reported myalgia 24 hours after completion of treatment #3

Sugar Water 24 Hours After Treatment #3

Ibuprofen 24 Hours After Treatment #3

Subject reported myalgia 48 hours after completion of treatment #3

Sugar Water 48 Hours After Treatment 3

Ibuprofen 48 Hours After Treatment 3

Myalgia Reported After Treatment #3

Subject self reported numerical rating of incidence and severity of Post ECT pain score for headache at 1, 6, 24 and 48 hours post procedure. Pain Rating 0= no pain, 2-4=moderate pain, 5-7=distressing severe pain, 8-9=intense very severe pain, 10=unbearable pain

500 mL of ringers lactate over 30 minutes to be administered prior to ECT for treatments 1
Placebo infusion: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatment day 1

Pain Score Sugar Water-one Hour After Treatment 1

800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1 one hour after treatment
ibuprofen intravenous: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT treatment day 2

Pain Score Ibuprofen One Hour After Treatment #1

Subject reported headache 6 hours after completion of treatment #1

Pain Score After Sugar Water 6 Hours After Treatment #1

Pain Score Ibuprofen 6 Hours After Treatment #1

Subject reported headache 24 hours after completion of treatment #1

Pain Score Sugar Water 24 Hours After Treatment #1

Subjects reported headache 24 hours after completion of treatment #1

Pain Score Ibuprofen 24 Hours After Treatment #1

Subjects reported headache 48 hours after completion of treatment #1

Pain Score Sugar Water 48 Hours After Treatment 1

Pain Score Ibuprofen 48 Hours After Treatment 1

Subject Self Reported Numerical Rating of Incidence and Severity of Post Electroconvulsive Therapy Headache After Treatment Day 1

Subject self reported numerical rating of incidence and severity of post ECT headache 0=no pain, 2-4=moderate pain, 5-7= distressing severe pain, 8-9= very severe pain, 10=unbearable pain.

800mg/8mL of intravenous ibuprofen over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments #2 one hour after treatment
ibuprofen intravenous: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT treatment day 2

Subject reported headache 6 hours after completion of treatment #2

Subject reported headache 24 hours after completion of treatment #2

Subject reported headache 48 hours after completion of treatment #2

Sugar Water 48 Hours After Treatment #2

Ibuprofen 48 Hours After Treatment #2

Incidence and Severity of Headache After ECT Treatment 2

Subject self reported numerical rating of incidence and severity of post ECT headache after treatment #3, 0=no pain, 2-4=moderate pain, 5-7=distressing severe pain, 8-9 very serious pain, 10=unbearable pain.

Subject reported headache 6 hours after completion of treatment #3

Subject reported headache 24 hours after completion of treatment #3

Subject reported headache 48 hours after completion of treatment #3

Incidence of Headache & Severity Headache After ECT Treatment #3

Overall Study

Vasanti Tilak, MD

Depression, Myalgia

Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3

Placebo infusion

IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3

phospholipase/galvassāpes

Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients

Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne